At this time, VICTRELIS (boceprevir) is not available in generic form. It is under the protection of patents, the first of which is set to expire in February 2022. After the patent expires, generic versions could be introduced. If you are having trouble affording VICTRELIS, your healthcare provider may have suggestions on how to lower your cost.
VICTRELIS™ (boceprevir) is a prescription medication approved for the treatment of chronic hepatitis C. It is only approved for use in combination with peginterferon alfa (Pegasys®, PEG-Intron®) and ribavirin (Copegus®, Rebetol®, Ribapak®, Ribasphere®).
VICTRELIS is made by Merck & Co., Inc. Currently, VICTRELIS is protected by patents that prevent any generic versions from being sold in the United States.
The first patent for VICTRELIS currently expires in February 2022. This is the earliest predictable date that a generic version could become available. However, this could change, depending on many factors, such as lawsuits or additional patents. Once the patent expires, there may be several companies that will manufacture a generic VICTRELIS drug.
No -- boceprevir is the active ingredient in VICTRELIS. It is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.